Aug 18, 2026 04:15AM
Aug 14, 2026 07:45AM
Jul 22, 2026 07:40AM
Jun 16, 2026 05:17AM
Jun 15, 2026 07:49AM
Jun 15, 2026 07:45AM
May 15, 2026 05:00PM TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Apr 22, 2026 07:30AM
Apr 22, 2026 07:30AM
Apr 1, 2026 07:45AM
Mar 24, 2026 10:30AM
Mar 23, 2026 07:45AM
Mar 23, 2026 07:45AM
Feb 17, 2026 07:46AM TuHURA files drug application for blood cancer treatment
Feb 17, 2026 07:45AM
Feb 2, 2026 07:45AM
Feb 2, 2026 07:45AM
Dec 11, 2025 07:30AM
Dec 11, 2025 07:30AM
Nov 14, 2025 07:00AM
Aug 14, 2025 04:15PM TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Jun 30, 2025 06:52AM
Jun 24, 2025 08:04AM
Jun 24, 2025 08:00AM
Jun 23, 2025 09:16AM
Jun 9, 2025 10:12AM
Jun 9, 2025 08:01AM
Jun 9, 2025 08:00AM FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
Jun 3, 2025 10:00AM
Jun 3, 2025 09:58AM
Jun 2, 2025 08:03AM
May 15, 2025 04:10PM
May 13, 2025 08:00AM
May 5, 2025 08:06AM
May 5, 2025 08:00AM TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary
Apr 1, 2025 08:00AM
Mar 11, 2025 08:05AM
Nov 25, 2024 08:39AM
Nov 25, 2024 08:35AM
Oct 17, 2024 04:38PM
Oct 17, 2024 04:35PM

330,173 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All